CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.

ABSTRACT: We investigated CD25 expression in older (≥60 years) patients with new acute myelogenous leukemia treated with decitabine and plerixafor. Patients resistant to therapy or survival ≤1 year had significantly higher percentages of CD25^pos myeloid blasts in baseline bone marrow. CD25^pos patients had an increased odds of resistance compared to CD25^neg patients (p = .015). In univariate analysis, we found CD25^pos patients had inferior survival compared to CD25^neg (p = .002). In patients with intermediate risk cytogenetics, CD25^pos status stratified patients associating with inferior survival (p = .002). In multivariable analysis, CD25 and TP53 mutations trended towards predicting remission to therapy but were not predictive of sur

SUBMITTER: Allan JN 

PROVIDER: S-EPMC5773411 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature